Cambridge, United States
Celsius Therapeutics, founded in 2018 and based in Cambridge, Mass., operates at the nexus of Biotechnology and Health Care. The company is on a mission to transform drug discovery through the power of single-cell genomics, as captured in their slogan: "On a quest to leverage the power of single cell genomics to discover novel drug targets and precision therapeutics."
With a collaborative and fast-paced environment, Celsius Therapeutics unites scientists, technologists, and clinicians to foster innovation. Their focus on single-cell RNA sequencing and genomic analysis aims to deliver life-changing medicines.
Recently, Celsius Therapeutics secured a significant $250.00M acquisition investment from AbbVie Ventures on 01 June 2024. This underlines strong confidence in their potential to impact human health positively. Positioned for growth, Celsius Therapeutics represents an appealing prospect for investors looking to fund breakthroughs in precision therapeutics.
Syntekabio Inc.
